RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Vivo Capital, a US-China healthcare investment firm, has raised $1.28 billion for its ninth fund, bringing its assets under management to more than $4.3 billion. Vivo invests in all stages of healthcare companies, from start-up to publicly owned. Founded in 1996, Vivo Capital is currently making investments from its $750 million eighth fund (2015) into private and public healthcare companies in the US and Greater China, from its $635 million Opportunity Fund (2018) into public healthcare companies, and from its $100 million PANDA Fund (2016) into early-stage innovative healthcare companies.
Source: China Biotoday
